Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion

Fang Zheng, Xiaohui SUO, Jie Liu, Liyun Zhao, Guanchen Bai, Xingli Zhao, Yanliang Bai, Dongmei Wang, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 3395.

https://doi.org/10.1182/blood-2025-3395

Published: 2025

Journal Articles

Synergistic integration of CAR-T cell pharmacokinetics and NGS-MRD evolution enables precision risk stratification in relapsed/refractory B-cell acute lymphoblastic leukemia

Runxia Gu, Shuning Wei, Shaowei Qiu, Xiaoyuan Gong, Guangji Zhang, Benfa Gong, Qiuyun Fang, Shouyun Li, Kaiqi Liu, Dong Lin, Ying Wang, Chunlin Zhou, Bingcheng LIU, Yingchang Mi, Hui Wei, Jianxiang Wang, Ying Wang

Blood (2025) 146 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2025-3366

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction treatment for patients with de novo acute leukaemias of ambiguous lineage

Xingli Zhao, Xiaohui SUO, Guanchen Bai, Yanliang Bai, Fang Zheng, Jie Liu, Ling Li, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 3451.

https://doi.org/10.1182/blood-2025-3451

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui SUO, Guanchen Bai, Yanliang Bai, Yunya Luo, Mei Lan, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Heng Li, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2025-3450

Published: 2025

Journal Articles

Front-line consolidation with CAR-t therapy in newly diagnosed adult ph-negative b-acute lymphoblastic leukemia: Results from a prospective, phase 2 study

Runxia Gu, Shaowei Qiu, Wenbing Liu, Xiaoyuan Gong, Shuning Wei, Guangji Zhang, Benfa Gong, Qiuyun Fang, Shouyun Li, Kaiqi Liu, Dong Lin, Ying Wang, Chunlin Zhou, Chengcai Guo, Bingcheng LIU, Yingchang Mi, Hui Wei, Ying Wang, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 1561.

https://doi.org/10.1182/blood-2025-1561

Published: 2025

Journal Articles

7-day venetoclax combined with intensive chemotherapy as induction treatment in newly diagnosed Acute Myeloid Leukemia with splicing factor gene mutations

Congcong Zhang, Xiaohui SUO, Xingli Zhao, Guanchen Bai, Yanliang Bai, Hongling Peng, Fang Zheng, Dongmei Wang, Liyun Zhao, ZePing Zhou, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 1618.

https://doi.org/10.1182/blood-2025-1618

Published: 2025

Journal Articles

7-day venetoclax combined with intensive chemotherapy as induction treatment in high-risk newly diagnosed Acute Myeloid Leukemia

Xiaohan Zhang, Xiaohui SUO, Guanchen Bai, Xingli Zhao, Yanliang Bai, Hongling Peng, Fang Zheng, Dongmei Wang, Liyun Zhao, ZePing Zhou, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 1617.

https://doi.org/10.1182/blood-2025-1617

Published: 2025

Journal Articles

Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study

Runxia Gu, Shaowei Qiu, Xiaoyuan Gong, Shuning Wei, Guangji Zhang, Benfa Gong, Qiuyun Fang, Shouyun Li, Kaiqi Liu, Dong Lin, Ying Wang, Chunlin Zhou, Chengcai Guo, Bingcheng LIU, Yingchang Mi, Hui Wei, Ying Wang, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 442.

https://doi.org/10.1182/blood-2025-442

Published: 2025

Journal Articles

Efficacy and safety of mini-CVD combined with venetoclax and azacitidine in acute leukemia of ambiguous lineage: A single-center retrospective study

Yan Li, Yue Shang, Kaiqi Liu, Yuntao Liu, Dong Lin, Jinsong He, Jiesi Li, Yanping Zeng, Hui Wei, Zhangsong Yan, Yingchang Mi

Blood (2025) 146 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2025-6864

Published: 2025

Journal Articles

Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui SUO, Guanchen Bai, Yanliang Bai, Yunya Luo, Mei Lan, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2025) 146 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2025-1675

Published: 2025

Journal Articles

Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

Blood (2024) 144 (Supplement 1): 4199.

https://doi.org/10.1182/blood-2024-200713

Published: 2024

Journal Articles

Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1 st Line Imatinib

Bingcheng Liu, Ying Wang, Kaiqi Liu, Yan Li, Qiuyun Fang, Yuntao Liu, Xiaoyuan Gong, Chunlin Zhou, Benfa Gong, Guangji Zhang, Shaowei Qiu, Hui Wei, Yingchang Mi, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 4533.

https://doi.org/10.1182/blood-2024-204887

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

ZePing Zhou, Yaxian Tan, Xingli Zhao, Xiaohui Suo, Guanchen Bai, Yanliang Bai, Yunya Luo, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2024) 144 (Supplement 1): 4279.

https://doi.org/10.1182/blood-2024-202430

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

Lei Ju, Xingli Zhao, Xiaohui Suo, ZePing Zhou, Yanliang Bai, Yunya Luo, Sifeng Gao, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Yaxian Tan, Guanchen Bai, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2024) 144 (Supplement 1): 1505.

https://doi.org/10.1182/blood-2024-202971

Published: 2024

Journal Articles

7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2885.

https://doi.org/10.1182/blood-2024-198844

Published: 2024

Journal Articles

Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Xiaoyuan Gong, Qiuyun Fang, Runxia Gu, Shaowei Qiu, Kaiqi Liu, Dong Lin, Chunlin Zhou, Shuning Wei, Guangji Zhang, Benfa Gong, Yuntao Liu, Yan Li, Shouyun Li, Bingcheng Liu, Wang Ying, Hui Wei, Yingchang Mi, Jianxiang Wang

Blood (2024) 144 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2024-199109

Published: 2024

Journal Articles

Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Blood (2024) 144 (Supplement 1): 1485.

https://doi.org/10.1182/blood-2024-203422

Published: 2024

Journal Articles

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial

Blood (2024) 144 (Supplement 1): 6035.

https://doi.org/10.1182/blood-2024-202495

Published: 2024

Journal Articles

Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia

Zepin Zhou, Xingli Zhao, Xiaohui Suo, Guanchen Bai, Zeyan Shi, Yunya Luo, Yaxian Tan, Xinxiao Lu, Linyu Yuan, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Heng Li, Weihua Zhao, Hongling Peng, Pengxiang Guo, Yingchang Mi, Kaiqi Liu

Blood (2023) 142 (Supplement 1): 1517.

https://doi.org/10.1182/blood-2023-179275

Published: 2023

Journal Articles

Three-Day Decitabine Combined with Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML

Xiaohui Suo, Guanchen Bai, Xingli Zhao, Congcong Zhang, Yinling Li, Sifeng Gao, Jilei Zhang, Xinxiao Lu, Linyu Yuan, Yingchang Mi, Kaiqi Liu

Blood (2023) 142 (Supplement 1): 5942.

https://doi.org/10.1182/blood-2023-181804

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) as induction treatment in newly diagnosed Acute Myeloid Leukemia with TP53-mutantion

Synergistic integration of CAR-T cell pharmacokinetics and NGS-MRD evolution enables precision risk stratification in relapsed/refractory B-cell acute lymphoblastic leukemia

Venetoclax combined with three-day multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction treatment for patients with de novo acute leukaemias of ambiguous lineage

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) VS venetoclax combined with azacitidine in elderly patients with Acute Myeloid Leukemia：a phase III, prospective, multicenter, randomized controlled trial

Front-line consolidation with CAR-t therapy in newly diagnosed adult ph-negative b-acute lymphoblastic leukemia: Results from a prospective, phase 2 study

7-day venetoclax combined with intensive chemotherapy as induction treatment in newly diagnosed Acute Myeloid Leukemia with splicing factor gene mutations

7-day venetoclax combined with intensive chemotherapy as induction treatment in high-risk newly diagnosed Acute Myeloid Leukemia

Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study

Efficacy and safety of mini-CVD combined with venetoclax and azacitidine in acute leukemia of ambiguous lineage: A single-center retrospective study

Venetoclax combined with three-day multi-frequency Decitabine (DEC3-VEN) in the treatment of adult patients with de novo Acute Myeloid Leukemia：updated results of a phase II trial

Inotuzumab Ozogamicin Administration in First Remission Results in Profound and Safe Minimal Residual Disease Eradication in Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia: Findings from a Phase 2, Single-Arm Trial

Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1 st Line Imatinib

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) in the Treatment of Adult Patients with De Novo Acute Myeloid Leukemia

Venetoclax Combined with Three-Day Multi-Frequency Decitabine and Homoharringtonine (DEC3-VEN-HHT) As Induction Therapy in Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia

7-Day Venetoclax Combined with Intensive Chemotherapy As Induction Treatment in Newly Diagnosed Acute Myeloid Leukemia

Improved MRD Clearance By Incorporating Venetoclax into Pediatric-Inspired Regimen in Newly Diagnosed Adolescent and Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Venetoclax Combined with Intensive Chemotherapy As an Induction Chemotherapy in Newly Diagnosed FLT3-ITD Positive AML

Venetoclax Combined with Three-Day Multi-Frequency Decitabine (DEC3-VEN) VS Venetoclax Combined with Azacitidine in Elderly Patients with Acute Myeloid Leukemia：a Phase III, Prospective, Multicenter, Randomized Controlled Trial

Venetoclax Combined with Homoharringtonine,Cytarabine and Aclacinomycin (HAAV) As Induction Therapy in Newly Diagnosed Young Adult Acute Myeloid Leukemia

Three-Day Decitabine Combined with Venetoclax in Patients with Newly Diagnosed or Relapsed/Refractory AML

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only